None
Quote | Arvinas Inc. (NASDAQ:ARVN)
Last: | $29 |
---|---|
Change Percent: | -0.21% |
Open: | $28.58 |
Close: | $29 |
High: | $29.49 |
Low: | $28.0228 |
Volume: | 626,734 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Arvinas Inc. (NASDAQ:ARVN)
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
2024-07-19 14:15:00 ET Summary We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt raises, warranting a sell. HubSpot faces volatil...
Message Board Posts | Arvinas Inc. (NASDAQ:ARVN)
Subject | By | Source | When |
---|---|---|---|
ARVN up 138% > "Based on data to | crudeoil24 | investorshub | 12/14/2020 2:19:37 PM |
Advantages of PROTACs vs. inhibition... | biocqr | investorshub | 12/17/2019 3:29:22 PM |
Idk about that, I thought it had some | G-lupo | investorshub | 11/29/2019 5:15:41 AM |
Starting to see a chink in the armor! | boo boo | investorshub | 11/26/2019 10:04:01 PM |
Possibly wall at 30.50 | G-lupo | investorshub | 11/15/2019 10:01:32 PM |
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...